Polymed Q4 FY26: Growth Returns, But Integration Takes the Margin Hit

Poly Medicure ended Q4 FY26 with a clear split between growth momentum and near term profitability pressure. On a standalone basis, revenue rose to Rs 443.0 crore, up 5.2 percent year on year, while operating EBITDA increased 4.2 percent to Rs 121.1 crore. But profit after tax declined 7.0 percent to Rs 80.6 crore, largely reflecting a softer other income line, higher depreciation, and a step up in finance costs.

The consolidated picture was more dramatic. Revenue jumped 21.3 percent year on year to Rs 534.5 crore in Q4, helped by the consolidation of acquisitions completed during FY26. Yet operating EBITDA fell to Rs 112.1 crore from Rs 121.9 crore last year, and the operating EBITDA margin compressed sharply to 21.0 percent from 27.6 percent. Management flagged that Q4 EBITDA was impacted by the consolidation of acquisitions and a one time provision related to regulatory and employee costs in a subsidiary. In other words, the quarter tells two stories at once: the platform is getting larger, but the newly added parts are still settling in.

A year of steady revenue, better gross margin, and lower reported returns

For FY26, standalone revenue increased 3.8 percent to Rs 1,662.5 crore. Gross margin improved meaningfully, with gross profit rising to Rs 1,132.0 crore and gross margin expanding to 68.1 percent from 66.8 percent in FY25. The company attributed this to an improving product mix and cost optimization initiatives.

Operating EBITDA, however, stayed flat at Rs 446.1 crore, and the operating EBITDA margin softened to 26.8 percent from 27.8 percent. This still landed near the top of the 25 to 27 percent guidance range communicated at the start of the year. PAT improved 1.4 percent to Rs 336.0 crore, showing that despite the subdued topline growth, profitability held up at the bottom line level.

Consolidated FY26 revenue rose 12.3 percent to Rs 1,875.3 crore, with gross margin expanding to 68.2 percent from 66.7 percent. But consolidated operating EBITDA was essentially flat at Rs 457.7 crore and the margin declined to 24.4 percent from 27.5 percent. Consolidated PAT fell 5.3 percent to Rs 320.7 crore.

The company also highlighted the context behind weaker return ratios in FY26. Consolidated RoCE was shown at 16 percent and ROE at 13 percent, with the note that returns were lower partly due to partial period consolidation of acquisitions. On a standalone basis, the company reported RoCE of 17.4 percent and RoIC of 21.4 percent, arguing that ROIC is a better lens during a high capex and investment phase, given the large amount of capital that is not yet deployed into revenue generating assets.

Mix is shifting: renal and others drive growth, infusion stays stable

Consolidated sales performance in FY26 shows that growth came from both geographies and portfolio expansion, but the contribution was uneven by segment.

Domestic revenue rose 19.6 percent year on year to Rs 581.7 crore, while international revenue increased 9.3 percent to Rs 1,280.2 crore. In Q4, domestic revenue growth was even stronger at 25.0 percent, while international grew 19.4 percent. The mix remained broadly stable: FY26 revenue was 31 percent domestic and 69 percent international, while Q4 FY26 was 32 percent domestic and 68 percent international.

By geography, FY26 revenue was evenly spread across India and Europe at 32 percent each, with the rest of world at 37 percent. Europe grew 7.1 percent in FY26, while rest of world grew 11.4 percent and India grew 19.6 percent. This balance matters for a company that positions itself as a global medical devices platform with distribution across 125 plus countries.

Segment wise, infusion therapy remained the anchor but was flattish. FY26 infusion therapy revenue was Rs 997.3 crore, down 1.5 percent from FY25. Renal care continued to scale rapidly, rising 24.5 percent to Rs 187.6 crore. The biggest acceleration came from the others segment, which grew 36.3 percent to Rs 690.4 crore. In Q4, others grew 55.2 percent year on year, indicating that the newer and higher technology parts of the portfolio are beginning to contribute more meaningfully.

What changed inside the business: acquisitions, product milestones, and capex

FY26 was not a simple year of organic scaling. It was a year where the group widened its technology curve and added new platforms. The company highlighted that acquisitions of PendraCare Group and Cittieffe Group are expected to create a roadmap for future growth in high end technology segments. Consolidated financials include PendraCare from 23 September 2025 and Cittieffe from 7 November 2025, which means the FY26 reported numbers capture only a partial period contribution.

This partial consolidation helps explain why revenue accelerated while margins fell, especially in Q4. The group is absorbing new cost structures, and management also cited a one time provision related to regulatory and employee costs in a subsidiary.

Operational updates in FY26 suggest the company is pushing into more complex therapies. Cumulative stent deployments crossed around 11,000 units by 30 April 2026. Commercial sales of DEB were initiated with positive clinician feedback. The PACIFER clinical registry for DES, covering 2,000 patients, had enrolled 650 plus patients, with enrollment expected to complete in FY27.

Renal continues to be a visible growth engine. The company sold 450 dialysis machines during FY26 and reported an installed base of around 1,000 machines. This reinforces the shift from being primarily a consumables exporter to building meaningful equipment and therapy platforms.

On market access, Polymed acquired Medynoe, a Brazil based medical device company holding registrations and operating licenses to commercialize operations. This sits alongside the broader international push, where the group is building direct presence through subsidiaries and acquisitions.

The investment intensity is evident in cash flow. In FY26, standalone capex was Rs 295.5 crore and consolidated capex was Rs 308.4 crore. In addition, investment in subsidiaries was Rs 439.9 crore standalone and Rs 386.0 crore consolidated. This translated into negative net cash flow generated of Rs 474.7 crore standalone and Rs 437.5 crore consolidated. Closing cash and cash equivalents remained sizable at Rs 796.8 crore standalone and Rs 842.2 crore consolidated.

Balance sheet trends show a bigger group and higher asset intensity. Consolidated goodwill rose to Rs 273.8 crore as at 31 March 2026, reflecting acquisitions. Intangible assets including under development rose to Rs 165.3 crore from Rs 26.6 crore, which aligns with the strategy of moving up the technology curve. Total debt increased to Rs 341.6 crore consolidated from Rs 177.6 crore, while cash remained high, supporting the company’s statement of adequate liquidity.

Working capital needs also rose on the standalone business. Debtor days increased to 98 from 78, and inventory days increased to 152 from 136, taking the cash conversion cycle to 215 days from 183 days. For investors, this is a key operational metric to track because it can influence near term cash generation even when reported profit remains stable.

Strategy narrative: building a global platform with a broader technology mix

Polymed’s long term message is consistent across the presentation: it wants to be a scaled, global medical devices platform with multiple growth engines. The group highlights 15 manufacturing plants across five countries, more than 1.8 billion devices of annual manufacturing capacity, and a presence in 125 plus countries supported by 1,000 plus distributors and 570 plus sales associates.

The flywheel described by management links clinical engagement to product development and then to scaled manufacturing and distribution. The company reported 4,000 plus annual customer engagement programs globally and 60 plus clinical experts. R and D capability is positioned as a core differentiator, with 390 plus patents granted, 60 applications under review, and a pipeline of 100 plus products to be launched in the next three to four years. FY26 saw 35 product launches, matching the count in FY25.

The emphasis on increasing the addressable market shows up in the portfolio roadmap. Infusion therapy is described as a global leadership area, and the company references being the third largest IV cannula manufacturer globally. But the strategic expansion is clearly toward renal care, critical care, cardiology, and orthopaedics. These are areas where clinical evidence, regulatory execution, and manufacturing quality matter more, and where acquisitions can accelerate capabilities.

Management also linked strategy to macro trends: rising prevalence of non communicable diseases, pressure on healthcare budgets, localization of manufacturing, and ESG as a differentiator. The company expects R and D expense, currently 1.7 percent of sales, to double in the next three to five years. This implies that product complexity will rise, and so will the need for disciplined execution to protect margins.

On sustainability, the company reported an approximate 8 percent reduction in scope 2 emissions compared to FY24-25 through increased use of solar and renewable energy PPA. It also stated that around 70 percent of facilities are ISO 14001:2015 certified. A 9.9 MWp solar project commissioned from 9 November 2025 generated about 3,297 MWh and reduced scope 2 emissions by about 2,341 tCO2.

Takeaways for investors: scale is improving, but FY27 must show cleaner conversion

Q4 FY26 reinforced that Polymed is entering a new phase. The topline is growing faster on a consolidated basis, driven by acquisitions and better domestic traction, and gross margins are improving. But operating margins in consolidated numbers have taken a hit in the integration phase, and working capital intensity remains elevated.

The company’s investment posture is clear. It spent heavily on capex and subsidiaries, built up intangible assets and goodwill through acquisitions, and continued to fund R and D and clinical evidence programs like the PACIFER registry. The reported RoIC of 21.4 percent on a standalone basis suggests the underlying business economics remain strong even during a heavy investment year.

The next test is execution quality in FY27: improving profitability of acquired entities, reducing one off impacts, converting the higher revenue base into stronger consolidated EBITDA, and keeping liquidity and working capital under control. If those pieces fall into place, FY26 may be remembered less for its slower standalone growth and more as the year the platform expanded to support the next leg of growth.